Selected papers on buprenorphine, BPD, the endogenous opioid system, and related mechanisms.
Buprenorphine is an opioid medication. Combining it with benzodiazepines, alcohol, or other central nervous system depressants increases the risk of respiratory depression. See the safety section on the treatment page.
Borderline Personality Disorder & the Endogenous Opioid System
Featured paper:
Borderline Personality Disorder: A Dysregulation of the Endogenous Opioid System? (2010)
Bandelow B, Schmahl C, Falkai P, Wedekind D
Proposes that core BPD behaviors can be understood as biologically mediated attempts to regulate a dysregulated endogenous opioid system rather than as purely impulsive or self-destructive acts — among them self-injury, substance use, frantic attachment, food restriction, and sensation seeking. Chronic emptiness and anhedonia may reflect reduced baseline opioid tone; the behaviors themselves may function as rapid methods of endogenous opioid activation.
The Interpersonal Dimension of Borderline Personality Disorder: Toward a Neuropeptide Model (2010)
Stanley B, Siever LJ
Builds a detailed neurobiological model positioning endogenous opioid, oxytocin, and vasopressin signaling as the core substrate of BPD's interpersonal dysregulation — connecting attachment disruption, separation distress, and social pain sensitivity to specific neuropeptide deficits rather than to general affective instability. Explicitly proposes that buprenorphine warrants investigation as a treatment for BPD.
An Opioid Deficit in Borderline Personality Disorder: Self-Cutting, Substance Abuse, and Social Dysfunction (2010)
New AS, Stanley B
Proposes that many core features of BPD — distress intolerance, interpersonal instability, self-injury, substance use — can be understood as attempts to temporarily correct an underlying endogenous opioid deficit, providing short-lived relief from emotional pain and emptiness.
Non-Suicidal Self-Injurious Behavior, Endogenous Opioids and Monoamine Neurotransmitters (2010)
Stanley B, Sher L, Wilson S, Ekman R, Huang YY, Mann JJ
Measured endogenous opioid levels directly in cerebrospinal fluid of Cluster B personality disorder patients. Those with NSSI histories had significantly lower CSF β-endorphin and met-enkephalin compared to matched patients without NSSI, while serotonin and dopamine metabolites did not differ. This implicates opioid deficiency specifically in self-injurious behavior and supports pharmacological investigation of the opioid system.
Some of the studies below use specialized neuroimaging or genetic methods; summaries are provided for accessibility.
Dysregulation of regional endogenous opioid function in borderline personality disorder (2010)
Prossin AR, Love TM, Koeppe RA, Zubieta JK, Silk KR
Using PET imaging, this study found that people with BPD show higher baseline μ-opioid receptor availability, interpreted by the authors as reflecting lower baseline endogenous opioid activity, along with abnormal opioid system responses during emotional distress. These findings provide direct biological evidence that the brain’s internal pain- and attachment-buffering system is dysregulated in BPD.
Differential methylation of OPRK1 in borderline personality disorder is associated with childhood trauma (2024)
Gescher DM, Schanze D, Vavra P, et al.
In people with BPD, this study found trauma-associated epigenetic changes in OPRK1, the gene encoding the κ-opioid receptor. The findings suggest long-term, trauma-linked alterations in the stress-related opioid system, which is known to drive dysphoria and aversive emotional states.
Taken together, these findings support a model in which borderline personality disorder involves both insufficient baseline μ-opioid signaling (contributing to chronic emptiness and social pain) and trauma-linked overactivation of the κ-opioid stress system (contributing to dysphoria, shutdown, and self-harm urges under stress). This dual dysregulation helps explain why treatments targeting only one pathway may be insufficient, and why medications like buprenorphine—which partially activate μ-opioid receptors while antagonizing κ-opioid receptors—are mechanistically well-suited to address core features of the disorder.
Buprenorphine for Depression & Suicidality
Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults (2014)
Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial (2016)
Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, Lotan A, Rigbi A, Panksepp J
Randomized controlled trial in which patients with severe suicidal ideation and no substance abuse received ultra-low-dose buprenorphine (starting 0.1–0.2 mg SL, titrated in 0.1 mg steps; mean dose 0.44 mg/day) or placebo. Buprenorphine produced rapid, significant reduction in suicidal ideation. Notably, the response was not attenuated in patients with BPD — who made up 56.8% of the sample — even though a BPD diagnosis typically predicts poorer outcomes in antidepressant trials. This makes it one of the strongest available controlled clinical signals for the BPD population.
Use of Buprenorphine in Treatment of Refractory Depression — A Review of Current Literature (2017)
Stanciu CN, Glass OM, Penders TM
Summarizes emerging evidence for buprenorphine’s antidepressant and anti-suicidal effects, including partial mu-agonism and kappa-antagonism mechanisms.
Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine (2021)
Cameron CM, Nieto S, Bosler L, Wong M, Bishop I, Mooney L, Cahill CM
A review synthesizing clinical and preclinical evidence for buprenorphine’s anti-suicidal potential, centered on its κ-opioid antagonist properties. The authors argue that emotional pain and separation distress — the PANIC/GRIEF system described by Panksepp — form a shared neurobiological pathway linking interpersonal rejection, suicidal ideation, and depression. People with BPD, they note, are especially prone to rejection-triggered suicidality. Buprenorphine is proposed to mitigate these negative affective states partly by dampening an overactive κ-opioid/dynorphin stress system.
Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder (2022)
Namchuk AB, Lucki I, Browne CA
A PRISMA-based review of the clinical evidence for buprenorphine in major depression, opioid use disorder, and suicidality. In opioid-naive patients with depression, low-dose buprenorphine consistently reduced depressive symptoms across trials, and it alleviated suicidal ideation in both opioid-naive and opioid-experienced patients. The authors trace these effects to buprenorphine’s mixed profile — partial μ-opioid agonism with κ-opioid antagonism — and conclude it is a promising therapeutic where depression and opioid use disorder co-occur.
Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial (2026)
Randomized, double-blind, placebo-controlled trial at Stanford in adults with MDD (or bipolar II) and active suicidal ideation. After a single intravenous ketamine infusion, participants received low-dose sublingual buprenorphine (0.2–0.8 mg/day) or matched placebo for 4 weeks. Both groups improved after ketamine, but the buprenorphine group showed significantly greater and more sustained reduction in suicidal ideation (mean SSI change −11.6 vs −6.3). No serious treatment-related adverse events occurred. The authors describe this as the first evidence that a pharmacological agent can sustain and enhance ketamine’s antisuicidal effects. In correspondence with the authors, they expressed hope to include patients with BPD in future trials.
The Use of Buprenorphine/Naloxone to Treat Borderline Personality Disorder: A Case Report (2022)
Hansen B, Inch KM, Kaschor BA
Documents an opioid-naive BPD patient initiated on buprenorphine/naloxone (Suboxone) at 2 mg and titrated stepwise to 6 mg, guided by crisis contact frequency as the functional endpoint. Over a 15-month comparison, crisis service contacts fell from 41 to 12, then to zero after dose optimization. Brief discontinuation during the study period was followed by hospitalization with symptoms consistent with pre-treatment baseline, which resolved on resumption — strengthening the case that improvement was attributable to the medication.
Buprenorphine in the Treatment of Non-Suicidal Self-Injury: A Case Series and Discussion of the Literature (2013)
Norelli LJ, Smith HS, Sher L, Blackwood TA
A case series of six long-term psychiatric inpatients with severe, treatment-refractory non-suicidal self-injury (NSSI), most carrying a borderline personality disorder diagnosis alongside extensive psychiatric comorbidity and histories of childhood trauma. After buprenorphine was added to their existing treatment, the group showed significant reductions in NSSI episodes, overall behavioral incidents, and emergency seclusion/restraint. The authors point to buprenorphine’s μ-opioid partial agonism and κ-opioid antagonism as the mechanistic rationale. This is a small, uncontrolled series in a complex and severely ill population, so the findings should be read as preliminary rather than definitive.